A PHASE-II STUDY OF AZIRIDINYLBENZOQUINONE (AZQ) IN ADVANCED LARGE BOWEL CARCINOMA

  • 1 January 1982
    • journal article
    • research article
    • Vol. 5  (5) , 539-540
Abstract
Aziridinylbenzoquinone (AZQ:NSC-182986), is a quinone derivative which has been shown to have antitumor activity. In a phase I study at the Mayo Clinic, dose-limiting toxicity was myelosuppression. Patients with prior radiation therapy or prior chemotherapy were more sensitive to this toxicity. A dose schedule of 27.5 mg/m2 q4 wk was recommended for patients who had had no previous chemotherapy and 22.5 mg/m2 for previously treated patients or for patients who had had extensive prior radiation therapy. The objective of this study was to determine therapeutic activity for AZQ in patients with advanced colorectal adenocarcinoma.

This publication has 0 references indexed in Scilit: